Gonadotropin-releasing hormone (GnRH) is a decapeptide released in pulsatile bursts from hypothalamic neurons, and it sits at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Every circulating hormonal feature of reproductive biology — menstrual cycling, testosterone production, puberty, fertility — depends on the frequency and amplitude of those GnRH pulses. Pharmacologically manipulating GnRH signaling is therefore one of the most powerful levers in endocrinology, and GnRH analogs are used across oncology, reproductive medicine, pediatric endocrinology, and gender-affirming care.
This guide covers the eight GnRH analogs most commonly encountered in clinical practice: the agonists leuprolide (Lupron), buserelin, histrelin (Vantas/Supprelin LA), nafarelin (Synarel), and alarelin; the antagonists cetrorelix (Cetrotide) and ganirelix (Ganirelix/Orgalutran); and the native synthetic decapeptide gonadorelin (Factrel), used primarily diagnostically and in specific pulsatile-dosing protocols. Understanding the distinction between agonists and antagonists — both mechanistically and clinically — is central to understanding how this drug class works.
GnRH analogs are FDA-approved and prescription-only across all indications covered here. They are not research peptides in the gray-market sense; most are stocked in hospital and specialty pharmacies and administered under protocols developed over decades. The guide emphasizes mechanism, indication, and key safety considerations rather than detailed dosing — for dosing and trial data, see each peptide's PeptaHub profile.
GnRH biology — hypothalamic pulsatility and LH/FSH regulation
GnRH is a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by roughly 1,000–3,000 neurons scattered across the preoptic area and medial basal hypothalamus. These neurons migrate from the olfactory placode during embryonic development, and failure of that migration causes Kallmann syndrome — congenital GnRH deficiency with anosmia. Mature GnRH neurons fire in synchronous bursts every 60–120 minutes, generating pulsatile GnRH release into the hypophyseal portal circulation.
The pituitary gonadotroph receives those GnRH pulses through the GnRH receptor (GnRHR), a G-protein-coupled receptor that signals primarily through Gq/11 to mobilize intracellular calcium and activate PKC. Each GnRH pulse triggers release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then act on gonadal tissue — testicular Leydig cells, ovarian theca and granulosa cells — to drive gametogenesis and steroidogenesis.
The defining feature of the GnRH system is pulse-frequency coding. Rapid GnRH pulses (every 30–60 min) favor LH release; slower pulses (every 120 min or longer) favor FSH. Continuous, non-pulsatile GnRH exposure has the opposite effect of pulsatile exposure: after an initial stimulation, the GnRH receptor downregulates and desensitizes, LH and FSH secretion falls, and gonadal steroid production collapses. This paradoxical response — continuous exposure causing suppression rather than stimulation — is the basis for how GnRH agonists are used therapeutically.
Agonists — flare then suppression (leuprolide, buserelin, histrelin, nafarelin, alarelin)
GnRH agonists are modified decapeptide analogs designed to bind the GnRH receptor with higher affinity than native GnRH and to resist degradation by endogenous peptidases. The result is sustained continuous receptor occupancy rather than the pulsatile signaling the receptor evolved to expect. The clinical effect unfolds in two phases.
In the first one to two weeks of therapy, an agonist produces a "flare" — a surge of LH and FSH, and therefore of testosterone or estradiol, above baseline. In prostate cancer patients this can transiently worsen bone pain, urinary obstruction, and spinal-cord compression if significant metastatic disease is present, which is why GnRH agonists are often co-administered with an androgen receptor antagonist (bicalutamide, flutamide) during the first two weeks to block the flare's downstream effect.
In the second phase, beginning around week 2–4, the GnRH receptor downregulates and desensitizes. LH and FSH fall sharply, and gonadal steroid production drops to castrate levels (<50 ng/dL testosterone in men; pre-menopausal estradiol levels in women). This profound suppression is the therapeutic endpoint.
The agonists covered here differ in their pharmacokinetic delivery profile more than in their mechanism. Leuprolide (Lupron) is available as 1-month, 3-month, 4-month, and 6-month depot injections; Histrelin (Vantas for prostate cancer, Supprelin LA for central precocious puberty) is delivered as a 12-month subcutaneous implant; Nafarelin (Synarel) is intranasal, dosed twice daily for endometriosis and central precocious puberty; Buserelin is delivered by subcutaneous injection or nasal spray depending on country and indication; Alarelin is a GnRH agonist primarily used in Chinese and Russian clinical practice and as a research peptide.
Antagonists — immediate suppression (cetrorelix, ganirelix)
GnRH antagonists occupy the GnRH receptor without activating it, blocking endogenous GnRH from binding and immediately suppressing LH and FSH release. Unlike agonists, antagonists do not cause a flare. Suppression begins within hours and can be titrated precisely. This rapid, flare-free suppression is particularly valuable in controlled ovarian stimulation for in-vitro fertilization (IVF), where the goal is to prevent a premature LH surge during the few days of follicular growth without prolonged gonadal shutdown.
Cetrorelix (Cetrotide) and ganirelix (Ganirelix Acetate, Orgalutran) are the two peptide GnRH antagonists in routine IVF practice. They are administered by subcutaneous injection during the follicular phase once follicles reach a defined size (typically 14 mm lead follicle diameter) or on a fixed protocol day (around cycle day 6). Both are eliminated within hours of the last dose, allowing rapid recovery of pituitary function and HCG-triggered ovulation.
Oral small-molecule GnRH antagonists have more recently expanded the clinical landscape beyond fertility — elagolix (Orilissa) for endometriosis and uterine fibroids, relugolix (Orgovyx, Myfembree) for prostate cancer and uterine fibroids. These are not peptides but they occupy the same receptor and have displaced some traditional GnRH agonist use. For IVF, the peptide antagonists cetrorelix and ganirelix remain standard.
Native GnRH — gonadorelin's diagnostic and pulsatile roles
Gonadorelin is synthetic native GnRH — the 10-amino-acid decapeptide identical to the hypothalamic hormone. Because it is rapidly degraded (plasma half-life of 2–4 minutes), gonadorelin is not useful as a sustained therapeutic; the same property that makes it the physiological signal also makes it a poor drug for chronic administration.
Gonadorelin has two established clinical uses. The first is diagnostic: a single IV or subcutaneous gonadorelin dose stimulates a measurable LH/FSH response from an intact pituitary, and this "GnRH stimulation test" is used to evaluate pubertal development, distinguish hypothalamic from pituitary causes of hypogonadism, and characterize HPG-axis integrity in various endocrinopathies. The second is pulsatile replacement: in patients with hypothalamic hypogonadotropic hypogonadism (including Kallmann syndrome), gonadorelin can be delivered by subcutaneous pump in physiologic pulses every 90–120 minutes to restore normal LH/FSH secretion and fertility. This pulsatile protocol is rarely used outside specialist centers because it is cumbersome compared with gonadotropin (HCG + FSH) replacement, but it remains a precise way to stimulate the pituitary in a patient whose defect lies upstream.
Outside those contexts, gonadorelin is not used chronically. The discussion in online peptide communities about using gonadorelin as a testosterone-axis supplement is not based on evidence from controlled trials — the peptide's 2–4-minute half-life means that subcutaneous daily or weekly dosing does not reproduce physiologic pulsatile signaling.
Clinical applications — IVF, prostate cancer, endometriosis, precocious puberty, transgender care
GnRH analog use spans a striking range of indications, connected by the common thread that each benefits from either controlled gonadal suppression (agonist) or rapid, reversible gonadal quieting (antagonist).
IVF is the largest-volume indication in many countries. GnRH agonists (leuprolide, buserelin) are used in "long protocol" IVF to suppress endogenous LH for several weeks before controlled ovarian stimulation with exogenous FSH; GnRH antagonists (cetrorelix, ganirelix) are used in "antagonist protocol" IVF to prevent premature LH surge during the shorter stimulation window. The antagonist protocol has become the more common choice in many centers because it is simpler and reduces ovarian hyperstimulation syndrome risk.
Prostate cancer is the highest-revenue indication for GnRH agonists. Leuprolide depot injections and histrelin implants are used for androgen-deprivation therapy in locally advanced, metastatic, and post-radiation prostate cancer. Oral relugolix has emerged as an alternative without the flare.
Endometriosis and uterine fibroids are treated with GnRH agonists (leuprolide depot, nafarelin nasal spray) to induce a reversible pseudo-menopause, reducing lesion size and symptoms. "Add-back therapy" (low-dose estradiol or norethindrone) is routinely given alongside to mitigate menopausal side effects.
Central precocious puberty is the primary pediatric indication. Histrelin implants (Supprelin LA) provide 12-month sustained GnRH agonist delivery to suppress premature pubertal progression, preserving adult height potential. Leuprolide depot is a common alternative.
Gender-affirming care uses GnRH agonists — particularly leuprolide and histrelin — as pubertal blockers in transgender adolescents, and occasionally in adults alongside exogenous sex-steroid hormones to suppress endogenous production. This use is clinically well-established within specialist protocols.
Safety and monitoring — hot flashes, bone loss, black box warnings
The safety profile of GnRH analogs is dominated by the consequences of sustained sex-steroid suppression. Hot flashes and night sweats are near-universal in both men and women on GnRH agonist therapy. Mood changes, decreased libido, erectile dysfunction (men), and amenorrhea (women) are also expected consequences of pharmacologic gonadal suppression.
Bone mineral density loss is the most important long-term concern. Chronic suppression of estradiol or testosterone accelerates bone remodeling toward resorption, producing measurable BMD decline within 6–12 months of therapy. For patients on short courses (IVF, 3–6 month endometriosis treatment), this is usually reversible and clinically insignificant. For patients on chronic therapy (prostate cancer, long-duration endometriosis), BMD monitoring (DEXA) and prophylactic bisphosphonate or denosumab therapy are considered depending on fracture risk.
Cardiovascular concerns have emerged in prostate cancer. Long-term androgen-deprivation therapy with GnRH agonists is associated with modest increases in cardiovascular events, metabolic syndrome, and diabetes risk. Whether GnRH antagonists (relugolix) carry a similar signal or a smaller one is under ongoing investigation. Several regulators have issued class-wide warnings.
In pediatric populations, the 2022 FDA label update added warnings for pseudotumor cerebri (idiopathic intracranial hypertension) in pediatric patients receiving GnRH agonist therapy. Long-term height and bone-density outcomes in transgender adolescents on extended blockade are a topic of active research and clinical monitoring.
Evolving use and the rise of oral small-molecule GnRH antagonists
The GnRH analog landscape in 2026 is being reshaped by the arrival of oral small-molecule GnRH antagonists. Elagolix (Orilissa) for endometriosis pain, relugolix in fixed-dose combinations (Myfembree, Ryeqo) for uterine fibroids and endometriosis, and relugolix monotherapy (Orgovyx) for prostate cancer all occupy the same GnRH receptor but as small molecules rather than peptides. Oral availability is the obvious advantage over depot injections or implants; titratability without waiting out an agonist flare is another.
This is not displacing peptide analogs entirely. Depot leuprolide and histrelin implants remain the dominant prostate cancer ADT choices in many practices because of cost, established reimbursement, and the clinical weight of decades of outcomes data. Peptide antagonists (cetrorelix, ganirelix) remain standard in IVF because their short half-life and injection-based delivery align with the stimulation window. And pediatric indications (central precocious puberty) are still exclusively served by peptide agonists, primarily histrelin implants.
The broader trend is a specialization of the GnRH pharmacology toolkit rather than a wholesale replacement. Clinicians now have choices along axes of route (IM/SC/implant/nasal/oral), onset kinetics (flare vs no flare), duration (1-month to 12-month), and reversibility. For patients, this often translates into less-intrusive therapy options than were available a decade ago.
Frequently asked questions
A GnRH agonist binds and activates the GnRH receptor continuously, causing an initial LH/FSH surge ("flare") followed by receptor downregulation and sustained gonadal suppression after 2–4 weeks. A GnRH antagonist binds the receptor without activating it, blocking endogenous GnRH and producing immediate suppression within hours, without a flare. Agonists are used when sustained suppression is the goal; antagonists when rapid reversible suppression is preferred.
Leuprolide suppresses gonadal steroid production after 2–4 weeks of continuous therapy, which is the therapeutic endpoint in prostate cancer (castrate-level testosterone) and the desired baseline state before controlled ovarian stimulation in long-protocol IVF. The underlying mechanism — GnRH receptor desensitization and HPG-axis shutdown — is identical across indications; only the dose, duration, and downstream hormone manipulation differ.
GnRH agonists bind the GnRH receptor more potently than native GnRH and resist peptidase degradation. The first 1–2 weeks of therapy produce sustained receptor activation, which initially drives LH and FSH (and therefore testosterone or estradiol) above baseline. Only after 2–4 weeks of continuous exposure does receptor downregulation and desensitization kick in, collapsing LH/FSH secretion and gonadal steroid production.
Gonadorelin is used primarily diagnostically — the GnRH stimulation test evaluates pubertal development and HPG-axis integrity. Its only routine therapeutic use is pulsatile pump delivery in hypothalamic hypogonadotropic hypogonadism (including Kallmann syndrome) to restore physiologic LH/FSH secretion and fertility. Its 2–4-minute half-life makes it unsuitable for chronic simple subcutaneous dosing; such use is not evidence-based.
Histrelin implants (Supprelin LA) provide 12 months of continuous subdermal GnRH agonist release from a single outpatient implantation procedure, avoiding monthly depot injections in pediatric patients. This delivery profile improves adherence and reduces injection-related distress. The sustained GnRH agonism suppresses pubertal progression and preserves adult height potential in children with central precocious puberty; the implant is replaced annually until the clinically appropriate age to allow pubertal progression.
Long-term GnRH agonist therapy suppresses sex-steroid production and produces hot flashes, mood changes, decreased libido, and progressive bone-mineral-density loss. Long-duration therapy (prostate cancer ADT, extended endometriosis treatment) is associated with modest increases in cardiovascular events and metabolic syndrome, prompting BMD monitoring and consideration of bisphosphonate or denosumab prophylaxis. Pseudotumor cerebri warnings exist for pediatric use.